Acrivon Therapeutics Inc., a clinical stage biotechnology company, has reported its financial results for the second quarter ended June 30, 2025. The company recorded a net loss of $21.0 million, compared to a net loss of $18.8 million for the same period in 2024. Research and development expenses rose to $16.2 million from $15.0 million in the previous year, primarily due to increased personnel supporting clinical trials for ACR-368 and ACR-2316, as well as advancements in preclinical drug discovery. General and administrative expenses were $6.5 million, remaining consistent with $6.4 million for the same period in 2024. Acrivon's continued advancement of clinical-stage assets includes ACR-368, which is in a registrational-intent Phase 2 study for endometrial cancer, and ACR-2316, currently in a Phase 1 study for AP3-predicted tumor types. The company highlighted the potential of ACR-368 to treat a wider patient population by combining it with ultra low-dose gemcitabine. The company also plans to report initial clinical data from the Phase 1 study of ACR-2316 in the second half of 2025. As of June 30, 2025, Acrivon had $147.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second quarter of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511947-en) on August 13, 2025, and is solely responsible for the information contained therein.
Comments